DelveInsight’s “Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Nonmelanoma Skin Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Nonmelanoma Skin Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Nonmelanoma Skin Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Nonmelanoma Skin Cancer: An Overview
The skin is made of a variety of cells, many of which are in constant motion. Round basal cells below the surface flatten as they rise to replace dead, flaking squamous cells on the surface. Melanocytes tan the skin in the sunlight, and Merkel cells give the skin its ability to sense touch. When these cells become damaged, they may develop into skin cancer.
Skin cancer can be further classified into melanoma and nonmelanoma. Skin cancers that are not melanomas are sometimes grouped as nonmelanoma skin cancers (NMSCs) because they develop from skin cells other than melanocytes. They tend to behave very differently from melanomas and are often treated with different methods.
Several types of skin cancer fall within the broader category of nonmelanoma skin cancer, but the primary forms are basal cell carcinoma and squamous cell carcinoma. Other types of NMSC are much less common than basal and squamous cell cancers and are treated differently. They include Merkel cell carcinoma, Kaposi sarcoma, Cutaneous (skin) lymphoma, and others.
The stages of nonmelanoma skin cancer are typically assigned on a scale of 0–4. Lower numbers indicate smaller, more contained tumors; higher numbers indicate larger cancers that have started to spread throughout the body.
When detected and treated early, common forms of nonmelanoma skin cancer can have a survival rate higher than 95%. This is because, in many cases of basal cell and squamous cell carcinoma, cancer can be removed entirely with the initial biopsy procedure alone.
In February 2021, the US FDA approved the PD-1 inhibitor LIBTAYO (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC, and accelerated approval was granted for patients with metastatic BCC.
Nonmelanoma Skin Cancer Market Key Facts
-
Basal cell carcinoma accounts for around 80% of skin cancer cases. It usually develops in places that have been exposed to the sun, such as the face and neck. Squamous cell carcinoma makes up roughly the other 20% of all cases of skin cancer.
-
Akdeniz et al. (2019) conducted a representative multicenter prevalence study in a random sample of ten institutional long-term care facilities in the federal state of Berlin, Germany. Nonmelanoma skin cancer was diagnosed in 7.2% of patients, and 6.7% of patients were also found to have basal cell carcinoma.
-
According to Cedars-Sinai (n.d.), skin cancer is the most common of all cancers. Between 40 and 50% of all cancer cases diagnosed every year are skin cancers. After treatment, basal cell carcinoma may grow again on the same spot or appear elsewhere on the skin. Between 35 and 50% of people who develop one basal cell carcinoma will grow a new skin cancer within five years of diagnosis.
Nonmelanoma Skin Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Nonmelanoma Skin Cancer pipeline therapies. It also thoroughly assesses the Nonmelanoma Skin Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Nonmelanoma Skin Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Nonmelanoma Skin Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Nonmelanoma Skin Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Nonmelanoma Skin Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Nonmelanoma Skin Cancer Epidemiology, Segmented as –
-
Total prevalent cases of NMSC in the 7MM (Basal cell carcinoma, Squamous cell carcinoma, and others) [2019–2032]
-
Total diagnosed prevalent cases of NMSC in the 7MM [2019–2032]
-
Region-specific diagnosed prevalent cases of NMSC in the 7MM [2019–2032]
-
Treatable cases of NMSC in the 7MM [2019–2032]
-
Age-specific diagnosed prevalent cases of NMSC in the 7MM [2019–2032]
-
Gender-specific diagnosed prevalent cases of NMSC in the 7MM [2019–2032]
Nonmelanoma Skin Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Nonmelanoma Skin Cancer market or expected to be launched during the study period. The analysis covers the Nonmelanoma Skin Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Nonmelanoma Skin Cancer drugs based on their sale and market share.
The report also covers the Nonmelanoma Skin Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Nonmelanoma Skin Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Nonmelanoma Skin Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/nonmelanoma-skin-cancer-market
Nonmelanoma Skin Cancer Therapeutics Analysis
Nonmelanoma skin cancer (NMSC) treatment is determined on a case-by-case basis, depending on many factors, such as the type and stage of cancer, the size and location of the tumor and the patient’s medical history and overall health. Nonsurgical treatments, such as freezing (cryotherapy), anti-cancer creams, photodynamic therapy (PDT), radiotherapy, and electrochemotherapy, are also used in certain circumstances.
Surgical excision is an operation to cut out cancer and the surrounding healthy tissue to eradicate cancer. Surgical excision may be combined with a skin graft, which involves removing a patch of healthy skin, usually from a part of the body where any scarring cannot be seen, such as your neck, abdomen, or upper thigh.
Drug therapy is sometimes used to treat NMSC. Topical therapy uses a cream or gel to put drugs directly on the skin. The topical therapy drugs used for non-melanoma skin cancer are imiquimod (ALDARA, ZYCLARA) and 5-fluorouracil (5-FU, EFUDEX, ACTIKERALL). Imiquimod is a type of immunotherapy drug called an immune response modifier. It uses the immune system to help destroy cancer cells. It may be used to treat small, superficial basal cell carcinoma (BCC) on the neck, trunk, arms, or legs. 5-fluorouracil is a chemotherapy drug used to treat a specific area of the skin. Topical 5-fluorouracil is used primarily for precancerous conditions of the skin, such as actinic keratosis.
Nonmelanoma Skin Cancer Companies Actively Working in the Therapeutics Market Include
-
Sirnaomics
-
AiViva BioPharma
-
Exicure
-
Sanofi
-
Genentech
And Many More
Emerging and Marketed Nonmelanoma Skin Cancer Therapies Covered in the Report Include:
-
VISMODEGIB (erivedge)
-
LIBTAYO (cemiplimab-rwlc)
-
STP705
-
AIV001
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/nonmelanoma-skin-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Nonmelanoma Skin Cancer Competitive Intelligence Analysis
4. Nonmelanoma Skin Cancer Market Overview at a Glance
5. Nonmelanoma Skin Cancer Disease Background and Overview
6. Nonmelanoma Skin Cancer Patient Journey
7. Nonmelanoma Skin Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Nonmelanoma Skin Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Nonmelanoma Skin Cancer Unmet Needs
10. Key Endpoints of Nonmelanoma Skin Cancer Treatment
11. Nonmelanoma Skin Cancer Marketed Therapies
12. Nonmelanoma Skin Cancer Emerging Drugs and Latest Therapeutic Advances
13. Nonmelanoma Skin Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Nonmelanoma Skin Cancer Market Outlook (In US, EU5, and Japan)
16. Nonmelanoma Skin Cancer Companies Active in the Market
17. Nonmelanoma Skin Cancer Access and Reimbursement Overview
18. KOL Views on the Nonmelanoma Skin Cancer Market
19. Nonmelanoma Skin Cancer Market Drivers
20. Nonmelanoma Skin Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/nonmelanoma-skin-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Osteogenesis Imperfecta Market
“Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Osteogenesis Imperfecta market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology